25 Jul 2019 17:12
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Result of AGM
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were passed on a show of hands. The results of the proxy voting for the AGM is set out below:
Resolution | Total votes For1 | % of votes cast2 | Total Votes Against | % of votes cast2 | Votes Withheld3 |
1. To receive the audited financial statements and the Auditor's and Directors' reports for the year ended 31 December 2018. | 84,274,491 | 99.99 | 7,976 | 0.01 | 1,130 |
2. To re-appoint Michael Bradfield as a Director of the Company. | 84,273,267 | 99.99 | 10,330 | 0.01 | 0 |
3. To appoint Chunlin Han as a Director of the Company. | 84,272,751 | 99.99 | 10,846 | 0.01 | 0 |
4. To re-appoint Hans von Celsing as a Director of the Company. | 84,273,267 | 99.99 | 10,330 | 0.01 | 0 |
5. To appoint Dr. Yuelong Huang as a Director of the Company. | 84,272,751 | 99.99 | 10,846 | 0.01 | 0 |
6. To re-appoint Prof Steve Myers as a Director of the Company. | 84,273,010 | 99.99 | 10,330 | 0.01 | 257 |
7. To re-appoint Dr Nick Plowman as a Director of the Company. | 84,273,010 | 99.99 | 10,330 | 0.01 | 257 |
8. To re-appoint Nicolas Serandour as a Director of the Company. | 84,273,010 | 99.99 | 10,330 | 0.01 | 257 |
9. To re-appoint Dr Michael Sinclair as a Director of the Company. | 84,272,844 | 99.99 | 10,496 | 0.01 | 257 |
10. To appoint Peter Sjöstrand as a Director of the Company. | 84,273,010 | 99.99 | 10,330 | 0.01 | 257 |
11. To appoint Prof. Gabriel Urwitz as a Director of the Company. | 84,273,010 | 99.99 | 10,330 | 0.01 | 257 |
12. To re-appoint Dr Enrico Vanni as a Director of the Company. | 84,273,010 | 99.99 | 10,330 | 0.01 | 257 |
13. To appoint Renhua Zhang as a Director of the Company. | 84,272,751 | 99.99 | 10,846 | 0.01 | 0 |
14. To re-appoint RPG Crouch Chapman LLP as Auditors | 84,274,104 | 99.99 | 7,976 | 0.01 | 1,517 |
15. To authorise the Directors to determine the remuneration of the Auditors. | 84,272,837 | 99.99 | 9,930 | 0.01 | 830 |
16. Authority to allot shares
| 84,267,634 | 99.98 | 15,797 | 0.02 | 166 |
17. Authority to disapply pre-emption rights
| 84,212,134 | 99.92 | 71,297 | 0.08 | 166 |
At the AGM the Company gave a presentation to shareholders. This will shortly be available on the website:
https://www.avoplc.com/Investor-Relations/Company-Documents
Notes:
1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution
Advanced Oncotherapy Plc | www.avoplc.com | |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0)20 3617 8728 | |
Nicolas Serandour, CEO | ||
Allenby Capital Limited (Nominated Adviser & Joint Broker) | ||
Nick Athanas / Liz Kirchner / Nicholas Chambers | Tel: +44 (0)20 3328 5656 | |
Stifel Nicolaus Europe (Joint Broker) | ||
Jonathan Senior | Tel: +44 20 7710 7600 | |
Walbrook PR (Financial PR & IR) | Tel: +44 (0)20 7933 8780 or avo@walbrookpr.com | |
Paul McManus / Anna Dunphy | Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001 | |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.
Due to the high cost of building and operating traditional proton therapy technologies has meant that the global capacity to treat cancer patients in this way has been extremely low. Only 1% of patients eligible for radiotherapy are being treated with proton therapy currently, with a capacity for as little as 60,000 patients to be treated annually across the globe. Considering the UK alone, where roughly 360,000 patients are diagnosed with cancer each year, it is clear that there is a desperate clinical need for the roll-out of a technology that can bring the benefits of proton beam therapy to millions of patients worldwide.